Literature DB >> 24062495

Embracing post-fertilisation methods of family planning: a call to action.

Elizabeth G Raymond1, Francine Coeytaux, Kristina Gemzell-Danielsson, Kirsten Moore, James Trussell, Beverly Winikoff.   

Abstract

Family planning methods that act when administered after fertilisation would have substantial benefits: they could be used longer after sex than current emergency contraceptives, and potentially a woman could use them only on relatively rare occasions when her menstrual period is delayed. Although such methods would displease abortion opponents, they would likely be welcomed by many women. Research to develop post-fertilisation fertility control agents should be pursued.

Entities:  

Keywords:  Abortion; Emergency Contraception; Hormonal Contraception

Mesh:

Year:  2013        PMID: 24062495      PMCID: PMC3855690          DOI: 10.1136/jfprhc-2013-100702

Source DB:  PubMed          Journal:  J Fam Plann Reprod Health Care        ISSN: 1471-1893


  17 in total

Review 1.  Synergistic effects of antiprogestins and iNOS or aromatase inhibitors on establishment and maintenance of pregnancy.

Authors:  Leili Shi; Shao-Qing Shi; Randall L Given; Helena von Hertzen; Robert E Garfield
Journal:  Steroids       Date:  2003-11       Impact factor: 2.668

2.  Do women want a once-a-month pill?

Authors:  C Rimmer; M Horga; V Cerar; E M Alder; D T Baird; A Glasier
Journal:  Hum Reprod       Date:  1992-05       Impact factor: 6.918

3.  Once-a-month treatment with a combination of mifepristone and the prostaglandin analogue misoprostol.

Authors:  M L Swahn; M Bygdeman; J K Chen; K Gemzell-Danielsson; S Song; Q Y Yang; P J Yang; M L Qian; W F Chang
Journal:  Hum Reprod       Date:  1999-02       Impact factor: 6.918

4.  Benefit-risk assessment of the levonorgestrel intrauterine system in contraception.

Authors:  Tiina Backman
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

5.  Relative contributions of anovulation and luteal phase defect to the reduced pregnancy rate of breastfeeding women.

Authors:  S Díaz; H Cárdenas; A Brandeis; P Miranda; A M Salvatierra; H B Croxatto
Journal:  Fertil Steril       Date:  1992-09       Impact factor: 7.329

6.  Mifepristone, but not levonorgestrel, inhibits human blastocyst attachment to an in vitro endometrial three-dimensional cell culture model.

Authors:  P G L Lalitkumar; S Lalitkumar; C X Meng; A Stavreus-Evers; F Hambiliki; U Bentin-Ley; Kristina Gemzell-Danielsson
Journal:  Hum Reprod       Date:  2007-09-21       Impact factor: 6.918

Review 7.  Interventions for emergency contraception.

Authors:  L Cheng; A M Gülmezoglu; G Piaggio; E Ezcurra; P F A Van Look
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

8.  Early luteal phase treatment with mifepristone (RU 486) for fertility regulation.

Authors:  K Gemzell-Danielsson; M L Swahn; P Svalander; M Bygdeman
Journal:  Hum Reprod       Date:  1993-06       Impact factor: 6.918

9.  Acceptability and feasibility of mifepristone-misoprostol for menstrual regulation in Bangladesh.

Authors:  Anadil Alam; Hillary Bracken; Heidi Bart Johnston; Sheila Raghavan; Noushin Islam; Beverly Winikoff; Laura Reichenbach
Journal:  Int Perspect Sex Reprod Health       Date:  2013-06

Review 10.  Experiences of abortion: a narrative review of qualitative studies.

Authors:  Mabel L S Lie; Stephen C Robson; Carl R May
Journal:  BMC Health Serv Res       Date:  2008-07-17       Impact factor: 2.655

View more
  3 in total

Review 1.  Emergency contraception. Widely available and effective but disappointing as a public health intervention: a review.

Authors: 
Journal:  Hum Reprod       Date:  2015-02-11       Impact factor: 6.918

Review 2.  Mechanism of action of levonorgestrel emergency contraception.

Authors:  Chris Kahlenborn; Rebecca Peck; Walter B Severs
Journal:  Linacre Q       Date:  2015-02

3.  The regulatory cliff edge between contraception and abortion: the legal and moral significance of implantation.

Authors:  Sally Sheldon
Journal:  J Med Ethics       Date:  2015-06-17       Impact factor: 2.903

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.